All News
Genetic Analysis of Asymptomatic Antinuclear Antibody Positive Patients
A large scale genomic population study found antinuclear antibodies (ANA) in up to 14% of the population; most with ANA are asymptomatic, and ANA production is not associated with significant genetic risk.
Genomics and Future Drug Targets for Osteoarthritis
d
EurekAlert!
A Nature article details the results of an osteoarthritis, genome-wide association study meta-analyses across up to 489,975 cases and 1,472,094 controls, establishing 962 independent associations, 513 of which have not been previously reported.
Read Article
Enzyme Porcupine inhibition of Wnt signaling is a promising treatment forsclerosteosis - rare Dz caused by SOST mutations & loss of functional sclerostin. Results in high bone mass & skeletal overgrowth (Sxs of facial paralysis, hearing loss, incr intracranial pressure https://t.co/9DYO82quiC
Dr. John Cush RheumNow ( View Tweet)
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF
Links:
Dr. John Cush RheumNow ( View Tweet)
Ultrasound lesions of dactylitis associ w/short-term development of PsA. Study of 64 PsO +arthralgia pts. IUS PD synovitis & B mode enthesitis predicted PsA Dx (p < .001) w/ an accuracy of 89.1 %, a sensitivity of 86.7 % and a specificity of 89.8 %. https://t.co/Ij6oYP1TuK https://t.co/55sO4uFXNI
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep 80mg vs PBO at wk 16 (52% vs 13%; p=0.0006) w/ 40mg=48%. Other arthritis, psoriasis, enthesitis, dactylitis, QOL outcomes also improved.https://t.co/CQn9EVjr9g https://t.co/vVnTo2FPV6
Dr. John Cush RheumNow ( View Tweet)
AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in 5 yrs of Dx best by iCCP3, RFIgA, RFIgM; and 104 proteins differentially expressed & gene analyses showed 21 pathways enriched ≤5 years of Dx. https://t.co/u8abvqNtnX
Dr. John Cush RheumNow ( View Tweet)
Daily purposeful walking assoc w/ lower risk of Knee OA (KOA). UK Biobank study of 89,969 persons, F/U 6.8 yrs - 2711 developed KOA. HRs for incident KOA were 0.84 (0.76-0.92), 0.81 (0.71-0.90), and 0.74 (0.64-0.85) if walking ~5000, ~7000, & ≥8000 steps/d, respectively https://t.co/St9QLuOy9R
Dr. John Cush RheumNow ( View Tweet)
Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and boosts remission rates without background immunosuppressants. CD19+ B-cell depletion shows promise as a new treatment. #Rheum @RheumNow https://t.co/7iSyPfnMV0 https://t.co/M51b0dipMs
Links:
Natasha Salman, DO DrNatashaSalman ( View Tweet)
✅ T2T in #Lupus 👀 ⬇️⬇️
📥 LINK https://t.co/F8w8qRZdsS
#NosVemosEnPANLAR2025 https://t.co/JNx1wdwMb4
Links:
Laurent ARNAUD Lupusreference ( View Tweet)
Our Chief Medical Editor Leonard H. Calabrese, DO, (@LCalabreseDO) shares his reflections on the book: Masterclass in Medicine: Lessons from the Experts
@ClevelandClinic
https://t.co/gZhbrBLcnR
Healio Rheumatology HealioRheum ( View Tweet)
Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/j8ZWFY4fgx
Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/uLoRmsAkiG https://t.co/ExthuSBSXs
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025 is now available On Demand
For the first time, https://t.co/4UQlqwujiR is offering exclusive access to:
✅ 7 STEP Talks from top rheumatology experts
✅ 21 Powerful lectures and Q & A Panels answering real-world questions
✅ All speaker slides and handouts https://t.co/saW9WH4djO
Links:
Dr. John Cush RheumNow ( View Tweet)
In a murine model of Kawasaki Dz vasculitis- depleting gut microbiota reduces KD like vasculitis. CV lesions were assoc w/ decrease in Akkermansia muciniphila and Faecalibacterium prausnitzii. Replacement attenuated these findings. https://t.co/Hnij8TWkYy https://t.co/wEuVcuAZ5j
Dr. John Cush RheumNow ( View Tweet)
Systematic review of >90 studies on Pregnancy and RA risk indicates that parity, gravidity, infertility, pregnancy loss do not adversely affect RA development. But low birthweight was assoc w/ RA Dx/severity, and pre-eclampsia incr risk of subsequent RA Dx. https://t.co/jVa4tmSqvj
Dr. John Cush RheumNow ( View Tweet)
Is High Dose Aspirin Needed in Kawasaki Disease (KD)?
Does aspirin add any advantage to intravenous immunoglobulin (IVIG) alone in children with KD? A randomized clinical trial IVIG alone was not inferior to IVIG plus aspirin, suggesting that high-dose aspirin during initial https://t.co/vThkP4AH6x
Dr. John Cush RheumNow ( View Tweet)
Recent Medscape Physician Compensation Report 2025, MD Salaries dropped by:
Dermatology: -11%
Neurology: -6%
Urology: -6%
Plastic surgery: -4%
Cardiology: -4%
Ophthalmology: -4%
Gastroenterology: -3%
Rheumatology: -3% https://t.co/WZDM7XxeEU https://t.co/PhRlHaXsMb
Dr. John Cush RheumNow ( View Tweet)
The IL-17A inhibitor, secukinumab, is in late-stage development forthe treatment of giant cell arteritis and polymyalgia rheumatica. https://t.co/JzzqS7bSjd https://t.co/9Qm0YsJmOL
Dr. John Cush RheumNow ( View Tweet)
FDA reports higher rate of allergic/hypersensitivity type reactions w/ certainlots of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) ; these have voluntarily withdrawn by the manufacturers https://t.co/j0yVBodLtW https://t.co/k7s4LtLnyu
Dr. John Cush RheumNow ( View Tweet)
